A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers
- Status
- COMPLETED
- Phase
- PHASE1
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
- Status
- COMPLETED
- Phase
- PHASE2
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
- Status
- TERMINATED
- Phase
- PHASE3
A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
- Status
- COMPLETED
- Phase
- PHASE3
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
- Status
- COMPLETED
- Phase
- PHASE2